Gastroenterology
Volume 130, Issue 4 , Pages 1311-1316 , April 2006

Recurrent Clostridium Difficile

  • Seema Maroo
    • ,
  • J. Thomas Lamont

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: J. Thomas Lamont, MD, 330 Brookline Avenue, Boston, Massachusetts 02215. fax: (617) 667-2767.

References 

  1. Kelly CP , Pothoulakis C , LaMont JT . Clostridium difficile colitis . N Engl J Med . 1994;330:257–262
  2. Fekety R  American College of Gastroenterology  Practice Parameters Committee . Guidelines for the diagnosis and management of Clostridium difficile–associated diarrhea and colitis . Am J Gastroenterol . 1997;92:739–750
  3. Tedesco FJ , Gordon D , Fortson WC . Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis . Am J Gastroenterol . 1985;80:867–868
  4. Bartlett JG , Tedesco FJ , Shull S , Lowe B , Chang T . Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis . Gastroenterology . 1980;78:431–434
  5. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease . JAMA . 1994;271:1913–1918
  6. Wenisch C , Parschalk B , Hasenhundle M , Hirschl A , Graninger W . Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea . Clin Infect Dis . 1996;22:813–818
  7. McFarland LV , Surawicz CM , Rubin M , Fekety R , Elmer GW , Greenberg RN . Recurrent Clostridium difficile disease (epidemiology and clinical characteristics) . Infect Control Hosp Epidemiol . 1999;20:43–50
  8. Kyne L , Kelly CP . Recurrent Clostridium difficile diarrhea . Gut . 2001;49:152–153
  9. Fekety R , McFarland LV , Surawicz CM , Greenberg RN , Elmer GW , Mulligan ME . Recurrent Clostridium difficile diarrhea (characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial) . Clin Infect Dis . 1997;24:324–333
  10. Triadafilopoulos G , Pothoulakis C , Weiss R , Giampaolo C , Lamont JT . Comparative study of Clostridum difficile toxin A and cholera toxin in rabbit ileum. Role of prostaglandins and leukotrienes . Gastroenterology . 1989;97:1186–1192
  11. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro . J Clin Invest . 1995;95:2004–2011
  12. Savidge TC , Pan WH , Newman P , O’Brien M , Anton PM , Pothoulakis C . Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine . Gastroenterology . 2003;125:413–420
  13. Walters BA , Roberts R , Stafford R , Seneviratne E . Relapse of antibiotic associated colitis (endogenous persistence of Clostridium difficile during vancomycin therapy) . Gut . 1983;24:206–212
  14. Young G , McDonald M . Antibiotic-associated colitis (Why do patients relapse?) . Gastroenterology . 1986;90:1098
  15. Wilcox MH , Fawley WN , Settle CD , Davidson A . Recurrence of symptoms in Clostridium difficile infection–relapse or reinfection? . J Hosp Infect . 1998;38:93–100
  16. Issack MI , Elliott TS . Clostridium difficile carriage after infection . Lancet . 1990;335:610–611
  17. Kyne L , Warny M , Qamar A , Kelly CP . Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A . N Engl J Med . 2000;342:390–397
  18. Leung DY , Kelly CP , Boguniewicz M , Pothoulakis C , Lamont JT , Flores A . Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin . J Pediatr . 1991;118:633–637
  19. Warny M , Vaerman JP , Avesani V , Delmee M . Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection . Infect Immun . 1994;62:384–389
  20. Kyne L , Warny M , Qamar A , Kelly CP . Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea . Lancet . 2001;357:189–193
  21. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O’Keane C, Gong D, et al. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor . J Clin Invest . 1992;90:822–829
  22. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T, Ryder RW, et al. Serum antibody response to toxins A and B of Clostridium difficile . J Infect Dis . 1983;148:93–100
  23. McFarland LV , Elmer GW , Surawicz CM . Breaking the cycle (treatment strategies for 163 cases of recurrent Clostridium difficile disease) . Am J Gastroenterol . 2002;97:1769–1775
  24. Tedesco FJ . Treatment of recurrent antibiotic-associated pseudomembrane colitis . Am J Gastroenterol . 1982;77:220–221
  25. Buggy BP , Fekety R , Silva J . Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin . J Clin Gastroenterol . 1987;9:155–159
  26. Elmer GW , Surawicz CM , McFarland LV . Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections . JAMA . 1996;275:870–876
  27. Surawicz CM , Elmer GW , Speelman P , McFarland LV , Chinn J , van Belle G . Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii (a prospective study) . Gastroenterology . 1989;96:981–988
  28. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease (use of high-dose vancomycin combined with Saccharomyces boulardii) . Clin Infect Dis . 2000;31:1012–1017
  29. Cherifi S , Robberecht J , Miendje Y . Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis . Acta Clin Belg . 2004;59:223–224
  30. Lestin F , Pertschy A , Rimek D . [Fungemia after oral treatment with Saccharomyces boulardii in a patient with multiple comorbidities] . Dtsch Med Wochenschr . 2003;128:2531–2533
  31. Sambol SP , Merrigan MM , Tang JK , Johnson S , Gerding DN . Colonization for the prevention of Clostridium difficile disease in hamsters . J Infect Dis . 2002;186:1781–1789
  32. Shim JK , Johnson S , Samore MH , Bliss DZ , Gerding DN . Primary symptomless colonization by Clostridium difficile and decreased risk of subsequent diarrhoea . Lancet . 1998;351:633–636
  33. Seal D , Borriello SP , Barclay F , Welch A , Piper M , Bonnycastle M . Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain . Eur J Clin Microbiol . 1987;6:51–53
  34. Gorbach SL , Chang TW , Goldin B . Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG . Lancet . 1987;2:1519
  35. Thomas MR , Litin SC , Osmon DR , Corr AP , Weaver AL , Lohse CM . Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea (a randomized, placebo-controlled trial) . Mayo Clin Proc . 2001;76:883–889
  36. Tvede M , Rask-Madsen J . Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients . Lancet . 1989;1:1156–1160
  37. Aas J , Gessert C , Bakken J . Recurrent Clostridium difficile colitis (case series involving 18 patients treated with donor stool administered via a nasogastric tube) . Clin Infect Dis . 2003;36:580–585
  38. Wilcox MH . Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea . J Antimicrob Chemother . 2004;53:882–884
  39. van Dissel JT, de Groot N, Hensgens CM, Numan S, Kuijper EJ, Veldkamp P, et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea (preclinical and preliminary clinical data) . J Med Microbiol . 2005;54:197–205
  40. Tedesco FJ , Napier J , Gamble W , Chang TW , Bartlett JG . Therapy of antibiotic-associated colitis . J Clin Gastroenterol . 1979;1:51–54
  41. Tedesco FJ . Treatment of antibiotic-associated colitis . Am J Gastroenterol . 1982;77:220–221
  42. Tedesco FJ . Pseudomembranous colitis (pathogenesis and therapy) . Med Clin North Am . 1982;66:655–664
  43. Kunimoto D , Thompson AB . Recurrent Clostridium difficile-associated colitis responding to cholestyramine . Digestion . 1986;33:225–228
  44. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis . Antimicrob Agents Chemother . 2001;45:2340–2347
  45. Louie T, Peppe J, Watt CK, Johnson D, Mohammed RA, Dow G, et al. A phase 2 study of the toxin binding polymer Tolevamer in patients with C. difficile-associated diarrhea . Gastroenterology . 2004;126(S2):A511
  46. Kotloff KL, Wasserman SS, Losonsky GA, Thomas W, Nichols R, Edelman R, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults . Infect Immun . 2001;69:988–995
  47. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, et al. Clostridium difficilevaccine and serum immunoglobulin G antibody response to toxin A . Infect Immun . 2003;71:1608–1610
  48. Sougioultzis S, Kyne L, Drudy D, Maroo S, Pothoulakis C, Giannasca PJ, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea . Gastroenterology . 2005;128:764–770

 Supported by NIH grants DK34583 and DK 07760.

PII: S0016-5085(06)00478-1

doi: 10.1053/j.gastro.2006.02.044

Gastroenterology
Volume 130, Issue 4 , Pages 1311-1316 , April 2006

Article Tools

* Image Usage & Resolution